From: Targeting cancers through TCR-peptide/MHC interactions
Antigen | Amino acid sequence of peptide | MHC molecule | Cancer | TCR used | Objective clincial response | Toxicity | Number of patients | References |
---|---|---|---|---|---|---|---|---|
MART-1 | AAGIGILTV | HLA-A*0201 | Melanoma | DMF4(human) | 2/17 (12%) | None | 17 | 103 |
MART-1 | AAGIGILTV | HLA-A*0201 | Melanoma | DMF5(human) | 6/20 (30%) | On-target toxicity on normal melanocytes (Skin rash (14/20), Uveitis (11/20), Hearing impairment (10/20)) | 20 | 105 |
MART-1 | EAAGIGILTV | HLA-A*0201 | Metastatic melanoma | 1D3HMCys(human) | 9/13(69%) | Mild skin rash (3/13) serious adverse events(2/13) due to cytokine release syndrome | 13 | 106 |
gp100 | KTWGQYWQV | HLA-A*0201 | Melanoma | gp100-154 (mouse) | 3/16 (17%) | On-target toxicity on normal melanocytes (Skin rash (15/16), Uveitis (4/16), Hearing impairment (5/16)) | 16 | 103 |
NY-ESO-1 | SLLMWITQC | HLA-A*0201 | Melanoma | 1G4-α95:LY(human) | 5/11 (45%) | None | 11 | 108 |
 |  | Synovial sarcoma |  | 4/6 (67%) |  | 6 |  | |
CEA | IMIGVLVGV | HLA-A*0201 | Metastatic colorectal cancer | L110F/S112T (mouse) | 1/3(33%) | Severe inflammatory colitis (3/3) due to on-target toxicity in colon | 3 | 113 |
MAGE-A3 | KVAELVHFL | HLA-A*0201 | Metastatic melanoma | MAGE-A3 A118T(mouse) | 5/9 (56%) | Central nervous system toxicities (Necrotizing leukoencephalopathy and death (2/9), Parkinson-like symptoms (1/9), Aphasia (1/9)) due to recognition of MAGE-A12 in the brain | 7 | 114 |
 |  | Synovial sarcoma |  |  |  | 1 |  | |
 |  | Esophageal cancer |  |  |  | 1 |  | |
MAGE-A3 | EVDPIGHLY | HLA-A*01 | Ulcerated melanoma | MAGE-A3a3a (human) | NA | Cardiac toxicity and death (2/2) due to cross-recognition of an unrelated epitope from Titin (TTN) | 1 | 119 |
 |  | Myeloma |  |  |  | 1 |  | |
MAGE-A4 | NYKRCFPVI | HLA-A*2402 | Esophageal cancer | MS-bPa(human) | 0/10 (0%) | None | 10 | 115 |
NY-ESO-1 | SLLMWITQC | HLA-A*0201 | Synovial cell sarcoma | 1G4-α95:LY (human) | 11/18 (61%) | None | 18 | 116 |
 |  | Melanoma |  | 11/20 (55%) |  | 20 |  | |
NY-ESO-1 | SLLMWITQC | HLA-A*0201 | Multiple myeloma | NY-ESOc259 (human) | 16/20 (80%) | None | 20 | 117 |
WT1 | CMTWNQMNL | HLA-A*2402 | AML and MDS | pMS3-WT1-siTCR(human) | 2/8 (25%) | None | 8 | 118 |